The therapeutic concept and analysis of the effect of hormone package therapy in brain dead organ donors

Authors

  • Guixing Xu Department of Neurosurgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
  • Ping Xu Department of Radiology, Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
  • Donghua Zheng Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
  • Wanjia Wei Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

DOI:

https://doi.org/10.18203/2349-2902.isj20194419

Keywords:

Brain death, Drug combination, Organ donation, Vasopressin, Thyroxine, Corticosteroids

Abstract

Background: The present study aimed to assess the effect of hormone package therapy on hemodynamic stability in brain dead organ donors.

Methods: In this study, patients were divided into two groups: one administered hormone package therapy, defined as simultaneous treatment with vasopressin, thyroxine and corticosteroids; and the other administered conventional therapy. Clinical findings and hemodynamic parameters were compared to analyze the effect of hormone package therapy on hemodynamic stability. Associations between hormone package therapy and hemodynamic variables were assessed by univariate and multivariate logistic regression analyses.

Results: A total of 109 patients were included in the study. Based on time of enrollment, 54 and 55 patients received conventional and hormone package therapy, respectively, with 32 (59.3%) and 45 (81.8%), respectively, achieving hemodynamic stability. High-doses of a single vasoactive agent in the hormone package group better maintained hemodynamic stability and norepinephrine use compared to conventional treatment. Univariate and multivariate analyses showed that an abnormal suprasellar cistern, midline shift, low free T3, axillary temperature >36.5°C and central diabetes insipidus were associated with the effects of hormone package therapy.

Conclusions: Hormone package therapy can help maintain hemodynamic stability in brain dead donors and reduce the use of vasoactive agents, thereby improving the quality of donated organs and the success rates of organ donations.

References

Brain Injury Evaluation Quality Control Centre of National Family Planning. Criteria and practical guidance for determination of brain death in adults (BQCC version). Chin Med J (Engl). 2013;126(24):4786-90.

Brain Injury Evaluation Quality Control Centre of National Family Planning. Criteria and practical for determination of brain death in children (BQCC version). Zhonghua Er Ke Za Zhi. 2014;52(10):756-9.

Plurad DS, Bricker S, Falor A, Neville A, Bongard F, Putnam, B. Donor hormone and vasopressor therapy: closing the gap in a transplant organ shortage. J Trauma Acute Care Surg. 2012;73(3):689-94.

Cooper DK. The Brain-Dead Organ Donor. In: Novitzky D, Cooper D, eds. Pathophysicology and Management. New York: Springer; 2013.

Cooper DK. Hormonal resuscitation therapy in the management of the brain-dead potential organ donor. Int J Surg. 2008;6(1):3-4.

Bugedo G, Bravo S, Romero C, Castro R. Management of the potential organ donor. Rev Med Chil. 2014;142(12):1584-93.

Novitzky D, Mi Z, Videla LA, Collins JF, Cooper DK. Hormone resuscitation therapy for brain-dead donors- is insulin beneficial or detrimental?. Clin Transplant. 2016;30(7):754-9.

Rosendale JD, Chabalewski FL, McBride MA, Garrity ER, Rosengard BR, Delmonico FL. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant. 2002;2(8):761-8.

Smetana KS, Kimmons LA, Jones GM. The role of hormone replacement therapy in the intensive care management of deceased organ donors: a primer for nurses. Crit Care Nurs Q. 2015;38(4):359-70.

Kotsch K, Ulrich F, Reutzel-Selke A, Pascher A, Faber W, Warnick P, et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. Ann Surg. 2008;248(6):1042-50.

Novitzky D, Mi Z, Videla LA, Collins JF, Cooper DK. Thyroid hormone therapy and procurement of livers from brain-dead donors. Endocr Res. 2016;41(3):270-3.

Novitzky D, Mi Z, Sun Q, Collins JF, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis. Transplantat. 2014;98(10):1119-27.

Novitzky D, Cooper DK, Rosendale JD, Kauffman HM. Hormonal therapy of the brain-dead organ donor: experimental and clinical studies. Transplantation. 2006;82(11):1396-401.

Piazza O, Scarpati G, Rispoli F, Iannuzzi M, Tufano R, De Robertis E. Terlipressin in brain-death donors. Clin Transplant. 2012;26(6):E571-5.

Muller E. Management of the potential organ donor in the ICU: Society of critical care Medicine/American College of chest Physicians/Association of Organ Procurement Organizations Consensus Statement. Transplantat. 2015;99(9):1743.

Kumar L. Brain death and care of the organ donor. J Anaesthesiol Clin Pharmacol. 2016;32(2):146-52.

Abdelnour T, Rieke S. Relationship of hormonal resuscitation therapy and central venous pressure on increasing organs for transplant. J Heart Lung Transplant. 2009;28(5):480-5.

Downloads

Published

2019-09-26

Issue

Section

Original Research Articles